CDT Equity Inc Dossier - Source-backed chat

CDT Equity Inc

CDTNASDAQ

SectorHealth Care

IndustryLife Sciences Tools & Services

Beta (adjusted)1.35

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.25Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $963.4K

Enterprise Value $416.4K

Shares Outstanding 13.7M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.) is a highly speculative, micro-cap biopharmaceutical development company that has transitioned to an asset-light, IP-focused model. The company leverages artificial intelligence (via its strategic stake in Sarborg Limited) and solid-form chemistry to enhance and out-license therapeutic assets. While the company's implied $127.5 million valuation of its Sarborg stake vastly exceeds its own micro-cap market capitalization (~$3.4 million to $5 million), CDT remains pre-revenue, is burning cash rapidly, and faces severe regulatory risks, including a Nasdaq deficiency notice for late financial filings. Recent debt restructuring has simplified its capital structure by eliminating $6.3 million in legacy debt, but near-term liquidity remains tight under a new weekly-amortizing loan facility. A 'Hold' rating is recommended, reflecting the binary nature of its clinical assets and the extreme volatility of its stock.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case is driven by structural distress, dilution, and regulatory failure. If CDT fails to file its Q1 2026 Form 10-Q or submit an acceptable compliance plan to Nasdaq, it faces delisting to the over-the-counter (OTC) market, severely damaging liquidity. Additionally, the company's rapid cash burn and the weekly amortization requirement of $82,125 under the JJ Astor loan facility could force highly dilutive equity raises. If clinical partnering discussions for AZD5904 stall or Sarborg's quantum computing initiatives fail to gain traction, the stock is highly likely to fall back below the critical $1.00 threshold and fade toward its 52-week low.

Base CaseCentral scenario

$1.0055%

In the base case, CDT Equity struggles to fully monetize its Sarborg stake in the near term due to liquidity constraints and lock-up provisions. The company will likely submit its Nasdaq compliance plan by the July 20, 2026 deadline and file its delayed Q1 2026 Form 10-Q, avoiding immediate delisting. However, the stock will continue to experience high volatility and trade near its current levels as it remains pre-revenue and relies on its at-the-market (ATM) program and the JJ Astor loan facility to fund operations. Progress on clinical asset partnering for AZD5904 will be slow but steady.

Bull CaseUpside scenario

$2.5025%

The bull case is centered on the massive valuation mismatch between CDT's market capitalization and its strategic assets. CDT's 1,020 shares in Sarborg Limited are valued at $127.5 million based on a June 2026 funding round at $125,000 per share, which implies a $638.3 million valuation for Sarborg. If Sarborg successfully commercializes its Signature Intelligence platform and launches its quantum computing division (SarborgQ), CDT could realize exponential value. Furthermore, successful out-licensing of its lead clinical assets, AZD5904 (for male infertility) and AZD1656 (for autoimmune disorders), would generate non-dilutive upfront and milestone payments, driving a powerful turnaround.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strategic 20% equity stake in Sarborg Limited, valued at an implied $127.5 million following a June 2026 fundraise, which represents a massive premium over CDT's own market cap.
Successful debt restructuring in June 2026 that eliminated over $6.3 million in legacy financing obligations (AGP and Ascent Partners), significantly simplifying the capital structure.
Asset-light, IP-centric business model focused on solid-form chemistry and AI-driven indication discovery, avoiding capital-intensive late-stage clinical trials.
Lead clinical assets (AZD5904 and AZD1656) have completed Phase I trials and are positioned for global patent protection and out-licensing partnering.

Key Investment Risks

Severe regulatory risk following a May 21, 2026 Nasdaq deficiency notice for failing to timely file the Q1 2026 Form 10-Q.
Pre-revenue status with zero operational revenue and a history of substantial net losses ($39.2 million net loss in FY 2025).
Tight near-term liquidity and cash burn, with the new $1.97 million JJ Astor loan facility requiring 24 weekly amortization payments of $82,125.
Extreme stock volatility and risk of falling below the Nasdaq minimum bid price requirement of $1.00, which could trigger delisting.

Thesis Invalidation Triggers

Failure to submit an acceptable compliance plan to Nasdaq by July 20, 2026, leading to formal delisting proceedings.
Default on the weekly amortization payments of $82,125 under the JJ Astor loan facility.
Inability to secure an out-licensing partner for AZD5904 within the next 12 months.
A material downward restatement of Sarborg Limited's valuation in subsequent funding rounds.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.